Echo Therapeutics Overview
Valuation check: ECTE's ROE is 96.14%, above the sector sector average of -5.72%.
Get informed when a big investor buys or sells
+ Follow96.14%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Echo Therapeutics posts a ROE of 96.14%. That is above the sector sector average of -5.72%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For its sector stocks, a ROE near -5.72% is typical. Echo Therapeutics's 96.14% is higher that level. That is roughly 1780.2% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Echo Therapeutics's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 96.14%; use YoY and peer views to separate noise from signal.
Context for ECTE's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -5.72%), and (3) consistency with growth and profitability. This page covers the first two; Echo Therapeutics's other metric pages and overview cover the third.
